Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 8, 2021
- Accepted in final form August 25, 2021
- First Published November 16, 2021.
Author Disclosures
- Marius Ringelstein, MD*,
- Ilya Ayzenberg, MD* (ilya.ayzenberg{at}ruhr-uni-bochum.de),
- Gero Lindenblatt, MD (g.lindenblatt{at}ak-neuss.de),
- Katinka Fischer, MSc (katinka.fischer{at}hhu.de),
- Anna Gahlen, MD (anna.gahlen{at}rub.de),
- Giovanni Novi, MD (giovanninovi{at}gmail.com),
- Helen Hayward-Könnecke, MD (helen.hayward-koennecke{at}triemli.zuerich.ch),
- Sven Schippling, MD (sven.schippling{at}roche.com),
- Paulus S. Rommer, MD (paulus.rommer{at}meduniwien.ac.at),
- Barbara Kornek, MD (barbara.kornek{at}meduniwien.ac.at),
- Tobias Zrzavy, MD (tobias.zrzavy{at}meduniwien.ac.at),
- Damien Biotti, MD (biotti.d{at}chu-toulouse.fr),
- Jonathan Ciron, MD (ciron.j{at}chu-toulouse.fr),
- Bertrand Audoin, MD (bertrand.audoin{at}ap-hm.fr),
- Achim Berthele, MD (achim.berthele{at}tum.de),
- Katrin Giglhuber, MD (katrin.giglhuber{at}mri.tum.de),
- Helene Zephir, MD (helene.zephir{at}chru-lille.fr),
- Tania Kümpfel, MD (tania.kuempfel{at}med.uni-muenchen.de),
- Robert Berger, MD (r.berger{at}asklepios.com),
- Joachim Röther, MD (j.roether{at}asklepios.com),
- Vivien Häußler, MD (v.haeussler{at}uke.de),
- Jan-Patrick Stellmann, MD (jan-patrick.stellmann{at}univ-amu.fr),
- Daniel Whittam, MD (daniel.whittam{at}nhs.net),
- Anu Jacob, MD (jacoba{at}clevelandclinicabudhabi.ae),
- Markus Kraemer, MD (markus.kraemer{at}krupp-krankenhaus.de),
- Antoine Gueguen, MD (agueguen{at}for.paris),
- Romain Deschamps, MD (rdeschamps{at}for.paris),
- Antonios Bayas, MD (antonios.bayas{at}klinikum-augsburg.de),
- Martin W. Hümmert, MD (huemmert.martin{at}mh-hannover.de),
- Corinna Trebst, MD (trebst.corinna{at}mh-hannover.de),
- Axel Haarmann, MD (haarmann_a{at}ukw.de),
- Sven Jarius, MD (sjarius{at}gmx.net),
- Brigitte Wildemann, MD (brigitte.wildemann{at}med.uni-heidelberg.de),
- Matthias Grothe, MD (matthias.grothe{at}uni-greifswald.de),
- Nadja Siebert, MD (nadja.siebert{at}charite.de),
- Klemens Ruprecht, MD (klemens.ruprecht{at}charite.de),
- Friedemann Paul, MD (friedemann.paul{at}charite.de),
- Nicolas Collongues, MD (nicolas.collongues{at}chru-strasbourg.fr),
- Romain Marignier, MD (romain.marignier{at}chu-lyon.fr),
- Michael Levy, MD (mlevy11{at}mgh.harvard.edu),
- Michael Karenfort, MD (michael.karenfort{at}med.uni-duesseldorf.de),
- Michael Deppe, PhD (deppe{at}uni-muenster.de),
- Philipp Albrecht, MD (phil.albrecht{at}gmail.com),
- Kerstin Hellwig, MD (k.hellwig{at}klinikum-bochum.de),
- Ralf Gold, MD (ralf.gold{at}rub.de),
- Hans-Peter Hartung, MD (hans-peter.hartung{at}uni-duesseldorf.de),
- Sven G. Meuth, MD (sven.meuth{at}uni-duesseldorf.de),
- Ingo Kleiter, MD* (ingo.kleiter{at}rub.de),
- Orhan Aktas, MD* (orhan.aktas{at}med.uni-duesseldorf.de);
- on behalf of the Neuromyelitis Optica Study Group (NEMOS)
- Marius Ringelstein, MD*,
1. Roche Pharma GmbH, served on a national scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.
NONE
1. Alexion, speaking honorarium. 2. Roche,speaking honorarium and funding for travel to a conference. 3. Biogen Idec, funding for travel to a conference.
NONE
NONE
NONE
NONE
1. Roche Pharma GmbH, served on a national and international scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ilya Ayzenberg, MD* (ilya.ayzenberg{at}ruhr-uni-bochum.de),
I took part in advisory boards of comercial pharmaceutrical companies Roche, Alexion, Merck.
NONE
I received speaker honoraria from Roche, Alexion, Merck Santhera companies.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I received research grant from Diamed Company.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gero Lindenblatt, MD (g.lindenblatt{at}ak-neuss.de),
NONE
NONE
(1) Bayer Healthcare, travel reimbursement
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katinka Fischer, MSc (katinka.fischer{at}hhu.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anna Gahlen, MD (anna.gahlen{at}rub.de),
NONE
NONE
(1) Sanofi Genzyme, travel reimbursement
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giovanni Novi, MD (giovanninovi{at}gmail.com),
(1) Served on a scientific advisory board for Merck and received speaker onoraria from Novartis and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Helen Hayward-Könnecke, MD (helen.hayward-koennecke{at}triemli.zuerich.ch),
(1) Biogen (2) Sanofi (3) Novartis (4) TEVA (5) Bayer
NONE
(1) Bayer (2) Sanofi
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Sven Schippling, MD (sven.schippling{at}roche.com),
NONE
NONE
NONE
Frontiers in Neurology (Neuroimmunology)
Therapeutic vaccination against JC virus mediated PML using the capsid peptides (incl. but not exclusively VP1).
NONE
I am an employee of Roche Pharma Research & Early Development (pRED), Neuroscience and Rare Diseases (NRD), Basel, Switzerland.
NONE
NONE
NONE
NONE
NONE
(1) Swiss National Science Foundation (SNF)
NONE
(1) Myelin Repair Foundation (USA)
NONE
NONE
NONE
NONE
NONE
NONE
- Paulus S. Rommer, MD (paulus.rommer{at}meduniwien.ac.at),
Alexion, Roche, Sanofi Genzyme, Sandoz, Amicus
NONE
NONE
Associate Editor : Frontiers in Neurology, Frontiers in Immunology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) Merck 2) Roche 3) biogen 4) Amicus
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Barbara Kornek, MD (barbara.kornek{at}meduniwien.ac.at),
Biogen, Sanofi-Genzyme, Merck, TEVA Aventis, Roche, BMS/Celgene, Novartis, Johnson&Johnson.
NONE
Travel honoraraia and honoraria for speaking from BMS/ Celgene, Merck, TEVA Aventis,Roche, Biogen, Sanofi-Genzyme, Novartis, Johnson&Johnson
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Zrzavy, MD (tobias.zrzavy{at}meduniwien.ac.at),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Damien Biotti, MD (biotti.d{at}chu-toulouse.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan Ciron, MD (ciron.j{at}chu-toulouse.fr),
Serving on Merck scientific board Serving on Roche scientific board Serving on Novartis scientific board Serving on Celgene scientific board Serving on Alexion scientific board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bertrand Audoin, MD (bertrand.audoin{at}ap-hm.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Achim Berthele, MD (achim.berthele{at}tum.de),
NONE
NONE
I received funding for travel and speaker honoraria from Alexion, Biogen, and Roche.
NONE
NONE
NONE
NONE
I have received consultancies from Alexion, Bayer Healthcare, Biogen, Celgene and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katrin Giglhuber, MD (katrin.giglhuber{at}mri.tum.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Helene Zephir, MD (helene.zephir{at}chru-lille.fr),
I received consulting fees from ROCHE, BIOGENIDEC, NOVARTIS, SANOFI, ALEXION.
NONE
NONE
NONE
NONE
NONE
NONE
I received consultancies fees from BIOGENIDEC, MERCK, BAYER, NOVARTIS, SANOFI, GENZYME, TEVA
NONE
NONE
NONE
I received research support grants from ROCHE
NONE
I received research support grants from Ligue Française contre la sclérose en plaques and from ARSEP (Association de recherche contre la Sclérose en plaques)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tania Kümpfel, MD (tania.kuempfel{at}med.uni-muenchen.de),
T. Kumpfel has served on advisory boards for Roche Pharma
NONE
T. Kumpfel has received personal compensations/speaker honoraria from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, Roche Pharma and Biogen as well as grant support from Novartis and Chugai Pharma in the past.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Robert Berger, MD (r.berger{at}asklepios.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joachim Röther, MD (j.roether{at}asklepios.com),
(1)Alexion(2)Boehringer Ingelheim(3)AstraZeneca(4)Bayer(5) Bristol Myers Squibb/Pfizer
NONE
(1)Alexion, speaker honoraria(2)Boehringer Ingelheim, speaker honoraria(3)AstraZeneca, speaker honoraria(4)Bayer, speaker honoraria(5)Bristol Myers Squibb/Pfizer, speaker honoraria
NONE
NONE
NONE
NONE
NONE
(1)Alexion, speaker honoraria(2)Boehringer Ingelheim, speaker honoraria(3)Sanofi Aventis, speaker honoraria(4)Bayer, speaker honoraria(5)Bristol Myers Squibb/Pfizer, speaker honoraria
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Vivien Häußler, MD (v.haeussler{at}uke.de),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jan-Patrick Stellmann, MD (jan-patrick.stellmann{at}univ-amu.fr),
Commercial - Genzyme Commercial - Alexion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial - Genzyme
BMBF, German competence Network Multiple sclerosis (KKNMs). (FKZ 01GI1602c) 2016-2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel Whittam, MD (daniel.whittam{at}nhs.net),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anu Jacob, MD (jacoba{at}clevelandclinicabudhabi.ae),
Novartis Roche
NONE
Viela Bio , Alexion Roche and Novartis
NONE
NONE
NONE
NONE
Roche
Veila Bio, Novartis , Roche
NONE
NONE
NONE
UK NHS -NMO service
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Markus Kraemer, MD (markus.kraemer{at}krupp-krankenhaus.de),
MK received honoraria for educational activities from Roche Pharma and Chugai Pharma.
NONE
Markus Kraemer received honoriaria for educational activities from Roche Pharma and Chugai Pharma.
Associate Editor of German DGNeurologie Journal.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Antoine Gueguen, MD (agueguen{at}for.paris),
Novartis Roche Merck Sanofi Alexon
NONE
Roche Teva Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Romain Deschamps, MD (rdeschamps{at}for.paris),
(1) Alexion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Antonios Bayas, MD (antonios.bayas{at}klinikum-augsburg.de),
(1) Merck Serono (2) Biogen (3) Novartis (4) TEVA (5) Sanofi/Genzyme (6) Roche (7) Alexion (8) Celgene (9) Janssen
NONE
(1) Merck Serono: travel, speaker honoraria, serving on scientific advisory boards (2) Biogen: travel, speaker honoraria, serving on scientific advisory boards (3) Novartis: travel, speaker honoraria, serving on scientific advisory boards (4) TEVA: travel, speaker honoraria, serving on scientific advisory boards (5) Sanofi/Genzyme: travel, speaker honoraria, serving on scientific advisory boards (6) Roche: speaker honoraria, serving on scientific advisory boards (7) Alexion: speaker honoraria, serving on scientific advisory boards (8) Celgene: travel, speaker honoraria, serving on scientific advisory boards (9) Janssen: serving on scientific advisory board
NONE
NONE
NONE
NONE
(1) Merck Serono (2) Biogen (3) Novartis (4) TEVA (5) Roche (6) Janssen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin W. Hümmert, MD (huemmert.martin{at}mh-hannover.de),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The NEMOS cohort/NationNMO is supported by the German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS).
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Corinna Trebst, MD (trebst.corinna{at}mh-hannover.de),
NONE
NONE
Speaker honoraria (educational efforts, CME activities) from Alexion Pharma Germany GmbH, Chugai Pharma Germany GmbH, and Roche Pharma GmbH
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Axel Haarmann, MD (haarmann_a{at}ukw.de),
NONE
NONE
(1) Alexion Pharmaceuticals, speaking fee.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sven Jarius, MD (sjarius{at}gmx.net),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brigitte Wildemann, MD (brigitte.wildemann{at}med.uni-heidelberg.de),
Brigitte Wildemann served on scientific advisory boards for Novartis, Sanofi Genzyme, Roche
NONE
Brigitte Wildemann has received personal fees from Alexion, Biogen, Merck Serono, Sanofi Genzyme, Novartis,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Brigitte Wildemann reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Forschung und Technologie, grants from Dietmar Hopp Stiftung, grants from Klaus Tschira Stiftung, grants from Merck Serono, Novartis Pharmaceuticals, and from Sanofi Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matthias Grothe, MD (matthias.grothe{at}uni-greifswald.de),
(1) Celgene (2) Merck Serono (3) Novartis (4) Roche (5)Sanofi Genzyme
NONE
(1) Novartis, funding for converence (2) Roche, funding for converence (3) Biogen, funding for converence
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nadja Siebert, MD (nadja.siebert{at}charite.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NS has received travel grants from Sanofi Genzyme, unrelated to the project.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klemens Ruprecht, MD (klemens.ruprecht{at}charite.de),
NONE
NONE
(1)Bayer Healthcare, speaker honoraria (2)Guthy Jackson Charitable Foundation, travel honoraria
(1) PLOS ONE, Academic Editor, since 2013
NONE
(1) Neurologie in Frage und Antwort, Elsevier, 2000-2015
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Merck Serono
(1) German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis) (2) European Union (821283-2)
NONE
(1) Dr. med. Arthur Arnstein Foundation (2) Stiftung Charité (BIH Clinical Fellow)
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD (friedemann.paul{at}charite.de),
Novartis OCTIMS study steering committee MedImmune / Viela Bio steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, Celgene
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- Nicolas Collongues, MD (nicolas.collongues{at}chru-strasbourg.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
N. Collongues serves on scientific advisory boards for and has received honoraria from Biogen Idec, Merck Serono, Sanofi-Genzyme, Bayer Schering Pharma, and Alexion Pharmaceutical.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Romain Marignier, MD (romain.marignier{at}chu-lyon.fr),
Dr Marignier is serving on a scientific advisory board of Viela Bio and UCB
NONE
Romain Marignier has received lecturing fees and travel grants from Biogen, Novartis, Roche, Sanofi, Alexion, UCB
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Levy, MD (mlevy11{at}mgh.harvard.edu),
NONE
NONE
NONE
Elsevier - Multiple Sclerosis and Related Disorders
NONE
NONE
NONE
Alexion, Genentech/Roche, Viela Bio
NONE
NONE
Neuromyelitis Optica Clinic - 20% effort Neuromyelitis Optica Research Lab - 80% effort
NONE
NIH/NIAID R01AI130548
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Karenfort, MD (michael.karenfort{at}med.uni-duesseldorf.de),
(1) Novartis advisory board
NONE
Speaker Honorar from Novartis Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Deppe, PhD (deppe{at}uni-muenster.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Philipp Albrecht, MD (phil.albrecht{at}gmail.com),
(1) Novartis, serving on an advisory board; (2) Biogen, serving on an advisory board; (3) Ipsen, serving on an advisory board; (4) Merck, serving on an advisory board; (5) Merz, serving on an advisory board; (6) Roche, serving on an advisory board; (7) Allergan, serving on an advisory board; (8) Celgene, serving on an advisory board; (9) Janssen Cilag, serving on an advisory board;
NONE
(1) Novartis, travel/accommodation/meeting expenses and speaker honoraria; (2)Teva, travel/accommodation/meeting expenses and speaker honoraria; (3) Biogen, travel/accommodation/meeting expenses and speaker honoraria; (4) Merz Pharmaceuticals, travel/accommodation/meeting expenses, (5) Ipsen, travel/accommodation/meeting expenses; (6) Esai, travel/accommodation/meeting expenses; (7) Glaxo Smith Kline, travel/accommodation/meeting expenses; (8) Bayer Healthcare, speaker honoraria, travel/accommodation/meeting expenses; (9) Allergan, speaker honoraria, travel/accommodation/meeting expenses; (10) Celgene, travel/accommodation/meeting expenses; (11) (9) Merck, speaker honoraria, travel/accommodation/meeting expenses;
(1) BMC Neuroscience, associate editor (2) Frontiers in Neurology, associate editor (3) Journal of Clinical Medicine, associate editor (4) Frontiers in Immunology, associate editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen (2) Novartis (3) Merz Pharmaceuticals (4) Ipsen (5) Roche (6) Allergan (7) Celgene
European Fund For Regional Development (EFRE.NRW)
NONE
(1) Doktor Robert Pfleger Stiftung (2) Iselore Luckow Stiftung (3) Europäischer Fonds für Forschung und Regionale Entwicklung (EFRE)
NONE
NONE
NONE
NONE
NONE
NONE
- Kerstin Hellwig, MD (k.hellwig{at}klinikum-bochum.de),
(1) Novartis (2) Genzyme (3) Teva (4) Merck (5) Roche
NONE
(1) Biogen, funding for travel (2) Novartis, funding for travel (3) Merck, funding for travel (4) Biogen Idec Germany, speaker honoraria (5) Teva, speaker honoraria (6) Sanofi Genzyme, speaker honoraria (7) Novartis, speaker honoraria (8) Bayer Healthcare, speaker honoraria (9) Merck Serono, speaker honoraria (10) Roche, speaker honoraria
NONE
NONE
NONE
NONE
NONE
Honoraria from Biogen, Bayer Healthcare, Teva, Sanofi, Merck and Novartis
NONE
NONE
Biogen, Bayer Healthcare, Teva, Merck, Roche, Sanofi- Genzyme and Novartis
(1) Fund of the Federal Joint Committee
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf Gold, MD (ralf.gold{at}rub.de),
(1) TEVA Laquinimod DSMB, AbbVie, Celgene
NONE
Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering, Celgene, Novartis, Roche, Eisai
SAGE Journal TAND, Experimental Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
research support from Biogen, Genzyme, Merck and Novartis
NONE
NONE
NONE
From Roche From Merck From Bayer
NONE
NONE
NONE
NONE
NONE
- Hans-Peter Hartung, MD (hans-peter.hartung{at}uni-duesseldorf.de),
Novartis; Merck Serono; Teva; Biogen; Roche; Genzyme; BayerHealthcare; Sanofi; MedImmune; GeNeuro; Octapharma; BMS Celgene; Roche; CSL Behring; TG Therapeutics; Viela Bio /Horizon Therapeutics
NONE
Speaker Honoraria from: Biogen Genzyme Merck Novartis Roche
editorial board member (unpaid): CNS Drugs; Frontiers Neurology / Immunology; European Neurology; Journal of Clinical Medicine; Current Opinion in Neurology; Nature Reviews Neurology; Therapeutic Advances in Neurological Disorders; Journal of Neuroinflammation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sven G. Meuth, MD (sven.meuth{at}uni-duesseldorf.de),
None
NONE
Sven G. Meuth received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva.
NONE
Effectivity of specific FXII/FXIIa inhibitors, especially rHA-Infestin-4, in treating neuroinflammatory diseases(WO 2013/113774 A1 und EP 2 263 110 A1) Biomarkers for diagnosis and management of neuro-immunological diseases(WO 2016/028699 A2) NR2B selective NMDA-Receptor antagonists for treatment of immune-mediated inflammatory diseases (Reference number: PCT/EP2016/069975) Detection of anti-neurochondrin autoantibody in patients with cerebellar ataxia or cerebellitis (US10,112,982B2) Diagnosis of a novel autoimmune disease (EP086120B1; US2018/0298072,A1)
NONE
NONE
NONE
NONE
NONE
NONE
SGM's research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva
SGM's research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster
NONE
SGM's research is funded by the German Foundation Neurology, Hertie Foundation, Else Kroner Fresenius Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Ingo Kleiter, MD* (ingo.kleiter{at}rub.de),
NONE
NONE
Alexion, Biogen, Celgene, Merck, Roche
Associate editor for BMC Neurology, Editorial board member Neuroimmunology Reports
NONE
NONE
NONE
Alexion, Biogen, Celgene, Merck, Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Orhan Aktas, MD* (orhan.aktas{at}med.uni-duesseldorf.de);
NONE
NONE
(1) Bayer, speaker honoraria (2) Novartis, speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck Serono, travel and speaker honoraria (5) Teva, speaker honoraria (6) Sanofi-Genzyme, speaker honoraria (7) Roche, travel and speaker honoraria (8) Almirall, speaker honoraria (9) Alexion, travel and speaker honoraria (10) Celgene, travel and speaker honoraria (11) Viela Bio, travel support
(1) PLoS ONE, Academic Editor, since 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis
(1) German Ministry of Science (BMBF), PI for NationNMO/KKNMS (NationNMO‐PAT FKZ 01GI1602B), since 2016
(1) German Research Foundation (DFG), PI in GRK2578, since 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- on behalf of the Neuromyelitis Optica Study Group (NEMOS)
- Department of Neurology (M.R., K.F., M.K.,P.A., H.P.H., S.G.M., O.A.), Medical Faculty, Heinrich Heine University Düsseldorf; Department of Neurology (M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University Düsseldorf; Department of Neurology (I.A., A.G., K.H., R.G., I.K.), St. Josef-Hospital, Ruhr University Bochum, Germany; Department of Neurology (I.A.), Sechenov First Moscow State Medical University, Russia; Department of Neurology (G.L.), Johanna Etienne Hospital, Neuss, Germany; Department of Neurology (G.N.), San Martino Hospital, Genova, Italy; Neuroimmunology and MS Research (H.H.K., S.S.), Department of Neurology, University Hospital Zürich, Switzerland; Department of Neurology (P.S.R., B.K., T.Z.), Medical University of Vienna, Austria; Department of Neurology (D.B., J.C.), B4 unit, CRC-SEP, Toulouse Purpan University Hospital, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) (D.B., J.C.) INSERM UMR1291-CNRS UMR5051 - Université Toulouse III, France; Aix Marseille University (B.A.), APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, Marseille, France; Technical University of Munich (A.B., K.G.), School of Medicine, Department of Neurology, Klinikum rechts der Isar, Germany; University of Lille (H.Z.), Inserm, CRC-SEP, CHU Lille, France; Institute of Clinical Neuroimmunology (T.K.), Faculty of Medicine, Ludwig Maximilian University, Munich; Department of Neurology (R.B., J.R.), Asklepios Klinik Altona, Hamburg; Department of Neurology and Institute of Neuroimmunology and MS (INIMS) (V.H.), University Medical Center Hamburg-Eppendorf, Germany; APHM, Hôpital de la Timone (J.P.S.), CEMEREM; Aix Marseille Univ, CNRS, CRMBM (J.P.S), UMR 7339, Marseille, France; Department of Neurology (D.W., A.J.), The Walton Centre, Liverpool, United Kingdom; the Cleveland Clinic Abu Dhabi, (A.J.) UAE; Department of Neurology (M.K.), Alfried Krupp Hospital, Essen, Germany; Department of Neurology (A.G.,R.D.), Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Department of Neurology (A.B.), Universitätsklinikum Augsburg; Department of Neurology (M.W.H., C.T.), Hannover Medical School; Department of Neurology (A.H.), University of Würzburg; Molecular Neuroimmunology Group (S.J., B.W.), Department of Neurology, University of Heidelberg; Department of Neurology (M.G.), University hospital Greifswald; NeuroCure Clinical Research Center and Experimental and Clinical Research Center (N.S., F.P), Max Delbrueck Center for Molecular Medicine and Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (K.R.), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin; Department of Neurology (N.C.), University Hospital Strasbourg; Service de neurologie (R.M.), sclérose en plaques, pathologies de la myéline et neuro-inflammation – Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, France; Department of Neurology (M.L.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of General Pediatrics (M.K.), Neonatology and Pediatric Cardiology, University Children's Hospital, Medical Faculty, Heinrich Heine University Düsseldorf; Department of Neurology (M.D.), University Hospital, Münster; and Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg, Germany.
- Correspondence
Dr. Ringelstein marius.ringelstein{at}med.uni-duesseldorf.de or Dr. Aktas orhan.aktas{at}med.uni-duesseldorf.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
RELATED MULTIMEDIA
Dr. Nicole Sur and Dr. Mausaminben Hathidara